The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CYBN | -48.9% | -70.66% | -20.29% | -77% |
| S&P | +14.5% | +93.32% | +14.09% | +88% |
Cybin, Inc. is a clinical-stage biopharmaceutical company. The company's mission is to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Its goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Their clinical programs and research-enabling technologies both surpass the competition.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | 62.3% |
| Market Cap | $176.49M | -14.3% |
| Market Cap / Employee | $3.53M | 0.0% |
| Employees | 50 | 0.0% |
| Net Income | -$24.61M | -127.2% |
| EBITDA | -$24.59M | -66.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $118.69M | -11.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.50M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -45.55% | 2.1% |
| Return On Invested Capital | -65.42% | -4.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.78M | -49.7% |
| Operating Free Cash Flow | -$29.55M | -48.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.85 | 0.93 | 0.76 | 1.10 | 15.23% |
| Price to Tangible Book Value | 1.21 | 1.39 | 1.18 | 1.80 | 35.23% |
| Return on Equity | -80.9% | -58.8% | -42.9% | -53.6% | 8.64% |
| Total Debt | $0.10M | $0.00M | $0.00M | $44.50M | 28622.44% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
